secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-03-02T23:59:59+00:00
Accession:  0001564590-22-008273
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio hires Alethia Young as CFO; Gutry steps down as PFO/PAO
--------------------------------------------------------------------

- Alethia Young appointed CFO effective April 1, 2022; previously senior biotech analyst at Cantor Fitzgerald.
- Base salary $450,000, target cash bonus 40% of salary, signing bonus $170,000.
- Relocation assistance $50,000/quarter for 12 months; initial option grant of 350,000 shares.
- Philip Gutry resigns as principal financial officer and principal accounting officer effective April 1, remains Chief Business Officer.
- Ms. Young will oversee finance, investor relations, corporate communications, and corporate strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022008273/0001564590-22-008273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022008273/grph-8k_20220302.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-008273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer